Alnylam reports early-phase data for brezosiran, an RNAi gene-silencing approach to Huntington's disease
Alnylam Pharmaceuticals says its investigational RNAi therapy brezosiran showed promising signals in an early study, adding to a competitive landscape of gene-silencing strategies for Huntington's disease.
Alnylam Pharmaceuticals has reported early-phase study data for brezosiran, an RNA interference (RNAi) agent designed to reduce expression of the mutant huntingtin (mHTT) protein that drives Huntington's disease. The company characterised the results as promising, though the study was early-stage and it remains to be seen whether the drug will demonstrate a meaningful effect on disease progression in larger, longer trials.
RNAi works by introducing short double-stranded RNA molecules that guide cellular machinery to degrade a specific messenger RNA before it can be translated into protein — in this case, the expanded CAG repeat-carrying HTT transcript responsible for the toxic gain-of-function in Huntington's disease. Brezosiran joins a field that includes antisense oligonucleotide (ASO) approaches from other developers, reflecting sustained interest in lowering mHTT as a therapeutic strategy.
Huntington's disease is a progressive autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4. Genetic testing can identify carriers of the expanded repeat, and the disease has a well-defined genetic cause, making it a natural target for gene-silencing strategies. Full data from Alnylam's early study have not yet appeared in peer-reviewed publications at the time of publication.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers at Alnylam Pharmaceuticals have shared early results for a new medicine called brezosiran, which is being tested as a treatment for Huntington's disease — an inherited condition caused by a change in a gene called HTT. Huntington's disease causes progressive problems with movement, thinking, and mood. Brezosiran is designed to reduce the amount of a harmful protein that the faulty gene produces, using a technology called RNA interference (RNAi), which can switch off the instructions a cell uses to make a specific protein. The early results were described as encouraging, but this is a small, early-stage study; the drug is not approved and further large trials are needed before its effectiveness and safety can be properly assessed. Several other companies are also developing medicines that aim to silence the Huntington's gene in different ways, showing this is an active research area. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-23STAT+: Alnylam says Huntington's drug shows promise in early study